Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Behandling med aspirin etter svangerskapsforgiftning: TAP-forsøk (TAP)

17. september 2026 oppdatert av: Malamo Countouris

The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.

Studieoversikt

Detaljert beskrivelse

This is a pilot randomized, single-center, double-blind placebo-control study of low dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or identical appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Rekruttering
        • University of Pittsburgh Magee-Womens Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alisse K Hauspurg, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Postpartum individuals ≥18 years old
  • Preeclampsia diagnosis

Exclusion Criteria:

  • Fetal anomaly
  • Multiple gestation
  • Pre-pregnancy hypertension
  • Allergy or contraindication to low-dose aspirin
  • Pre-pregnancy diabetes

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo Group

Similar appearing placebo pill daily for 6 months will be given to subjects.

The control group will receive similar appearing placebo daily for 6 months.

Eksperimentell: Intervention Group

Low-dose [81 mg] aspirin pill daily for 6 months will be given to subjects

The intervention group will receive low-dose [81 mg] aspirin pill daily for 6 months.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percent of participants eligible, enrolled and retained (feasibility)
Tidsramme: Baseline to approximately 6 months postpartum

To determine the feasibility of conducting a single-site randomized controlled trial of 6 months of postpartum low-dose aspirin vs. placebo in women with preeclampsia.

Baseline to approximately 6 months postpartum

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Study visit systolic BP
Tidsramme: 2 months postpartum

Mean study visit systolic BP

2 months postpartum
Study visit diastolic BP
Tidsramme: 2 months postpartum

Mean study visit diastolic BP

2 months postpartum
Study visit systolic BP
Tidsramme: 6 months postpartum

Mean study visit systolic BP

6 months postpartum
Study visit diastolic BP
Tidsramme: 6 months postpartum

Mean study visit diastolic BP

6 months postpartum
Study visit mean arterial pressure
Tidsramme: 2 months postpartum

Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3))

2 months postpartum
Study visit mean arterial pressure
Tidsramme: 6 months postpartum

Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3))

6 months postpartum
Anti-hypertensive medication use
Tidsramme: 2 months postpartum

Use of anti-hypertensive medication (percent of participants)

2 months postpartum
Anti-hypertensive medication use
Tidsramme: 6 months postpartum

Use of anti-hypertensive medication (percent of participants)

6 months postpartum
Therapeutic intensity score
Tidsramme: 2 months postpartum

Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome)

2 months postpartum
Therapeutic intensity score
Tidsramme: 6 months postpartum

Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome)

6 months postpartum
Mean home systolic blood pressure
Tidsramme: delivery through 6 months postpartum

Mean home systolic blood pressure

delivery through 6 months postpartum
Mean home diastolic blood pressure
Tidsramme: delivery through 6 months postpartum

Mean home diastolic blood pressure

delivery through 6 months postpartum
Mean home mean arterial pressure
Tidsramme: delivery through 6 months postpartum

Mean home mean arterial pressure

delivery through 6 months postpartum
Mean daytime systolic blood pressure
Tidsramme: 6 months postpartum

Mean daytime systolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean nocturnal systolic blood pressure
Tidsramme: 6 months postpartum

Mean nocturnal systolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean daytime diastolic blood pressure
Tidsramme: 6 months postpartum

Mean daytime diastolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean nocturnal diastolic blood pressure
Tidsramme: 6 months postpartum

Mean nocturnal diastolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean nocturnal mean arterial pressure
Tidsramme: 6 months postpartum

Mean nocturnal mean arterial pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean daytime mean arterial pressure
Tidsramme: 6 months postpartum

Mean daytime mean arterial pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean overall mean arterial pressure
Tidsramme: 6 months postpartum

Mean overall mean arterial pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean overall systolic blood pressure
Tidsramme: 6 months postpartum

Mean overall systolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean overall diastolic blood pressure
Tidsramme: 6 months postpartum

Mean overall diastolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Classification of hypertension
Tidsramme: 2 months postpartum

Stage 1, stage 2 hypertension (percent of participants with each stage)

2 months postpartum
Classification of hypertension
Tidsramme: 6 months postpartum

Stage 1, stage 2 hypertension (percent of participants with each stage)

6 months postpartum
Endothelial function EC50%
Tidsramme: 2 months postpartum

EC50% from microiontophoresis

2 months postpartum
Endothelial function EC50%
Tidsramme: 6 months postpartum

EC50% from microiontophoresis

6 months postpartum
Endothelial function Emax
Tidsramme: 2 months postpartum

Emax from microiontophoresis

2 months postpartum
Endothelial function Emax
Tidsramme: 6 months postpartum

Emax from microiontophoresis

6 months postpartum
Endothelial function change in Emax
Tidsramme: 2 to 6 months postpartum

Change in Emax between visits

2 to 6 months postpartum
Endothelial function change in EC50%
Tidsramme: 2 to 6 months postpartum

Change in EC50% between visits

2 to 6 months postpartum
Change in systolic blood pressure
Tidsramme: 2 to 6 months postpartum

Change in study visit mean systolic blood pressure between visits

2 to 6 months postpartum
Change in diastolic blood pressure
Tidsramme: 2 to 6 months postpartum

Change in study visit mean diastolic blood pressure between visits

2 to 6 months postpartum
Change in mean arterial pressure
Tidsramme: 2 to 6 months postpartum

Change in study visit mean arterial pressure between visits

2 to 6 months postpartum

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Alisse K Hauspurg, MD, UPMC Magee Women's Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. mai 2024

Primær fullføring (Antatt)

1. januar 2027

Studiet fullført (Antatt)

1. oktober 2027

Datoer for studieregistrering

Først innsendt

15. februar 2024

Først innsendt som oppfylte QC-kriteriene

19. februar 2024

Først lagt ut (Faktiske)

28. februar 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Deidentified data (including data dictionaries) will be shared at the discretion of the primary investigator. Data will include blood pressure, weight, demographics, physical activity, and pregnancy related information. Additional documents (such as the study protocol) will be made available.

IPD-delingstidsramme

Within a year after outcomes are published and no later than 3 years after the end of clinical activities.

Tilgangskriterier for IPD-deling

NHLBI data repository request process

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere